Multiple Manufacturers

DACOGEN

Manufacturer:

Multiple Manufacturers

Dacogen HCPCS:

J0894

HCPCS Code Descriptor:

Injection, decitabine, 1 mg

Category:

J Code

Dacogen NDCs:

59148-0046-70, 00781-3139-80, 16714-0928-01, 72603-0107-01, 70121-1644-01, 68001-0422-37, 55111-0556-10, 43598-0348-37, 43598-0427-37, 67457-0316-25, 50742-0430-01, 68001-0573-41, 63323-0825-20, 75834-0190-01, 55150-0376-01, 70860-0219-20, 72205-0031-01, 72205-0036-01, 69097-0905-67, 16729-0224-05, 25021-0231-20, 71288-0119-20, 00143-9385-01

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

59148-0046-70, 00781-3139-80, 16714-0928-01, 75834-0190-01, 70860-0219-20, 16729-0224-05

About Dacogen:

DACOGEN is an Oncology drug manufactured by Otsuka America and administered via the Intravenous route of administration. The J Code: J0894 is aligned to the drug DACOGEN.

ACCESS PRICING AND MORE BY REGISTERING

J0894 Added Date:

January 1, 2007

J0894 Effective Date:

January 1, 2023

J0894 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Dacogen billing and coding information.
Our team did not identify a source for Dacogen patient assistance information. Please reach out to our team if you feel that this is a mistake.
DACOGEN prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for DACOGEN. Please check back in a few weeks.